



IRC
Impact Research Communications



**GLOBAL VIRTUAL CONFERENCE
ON LEISHMANIASIS
SEPTEMBER 30, 2025 | ONLINE**

Scientific Program

Time zone: Eastern Time (USA)

08:00-08:10 Opening Remarks

08:10-08:40 Shyam Sundar, Banaras Hindu University, India
Elimination of visceral leishmaniasis from India – The story

08:40-09:10 Sébastien Pomel, University of Paris-Saclay, France
Targeting the host cell as a new strategy for the treatment of leishmaniasis

09:10-09:40 Debabrata Mandal, NIPER Hajipur, India
Metallic Nanoparticles of Amphotericin b for reduced cytotoxicity and antileishmanial efficacy – Synthesis, characterization and biological studies

09:40-10:00 Muhammad Manjurul Karim, University of Dhaka, Bangladesh
Development of a patient-friendly molecular diagnostic for human visceral leishmaniasis: A giant step forward towards its elimination

10:00-10:10 Break

10:10-10:40 Abhay Satoskar, Ohio State University, OH, USA
Development of Leishmania antigen for LST as a surrogate marker for immunogenicity

10:40-11:10 Hira L. Nakhasi, Center of Biologics Research and Evaluation (CBRE), FDA, MD, USA
Advancement in Leishmania vaccination development and its role in global elimination of leishmaniasis

11:10-11:40 Elyes Zhioua, Institut Pasteur de Tunis, Tunisia
Co-circulation of *Leishmania infantum* and Toscana virus in sandflies and dogs in a focus of canine leishmaniasis of Northern Tunisia

11:40-12:10 Kwang Poo Chang, Rosalind Franklin University, IL, USA
Immunotherapy of canine leishmaniasis with singlet oxygen-killed *Leishmania infantum*

12:10-12:40 Nicola Baker, University of York, United Kingdom
Making sense of how Leishmania detect changes in pH

12:40-12:50 Break

12:50-13:20 Andreia Albuquerque Wendt, GHTM/IHMT-UNL, Portugal and PCU/Swiss TPH, Switzerland and Charles University, Czech Republic
Essential role of vacuolar H⁺-ATPase in Leishmania life cycle progression

13:20-13:50 Danilo Ciccone Miguel, State University of Campinas, Brazil
Natural and synthetic leishmanicidal candidates: From bench to mechanistic insights in causative agents of new world cutaneous leishmaniasis

13:50-14:20 Kishor Wasan, University of British Columbia, Canada
Development of a novel oral formulation of Amphotericin B to treat Visceral Leishmaniasis (VL) in vulnerable populations

14:20-14:50 Claudia Brodskyn, Oswaldo Cruz Foundation, Brazil
Aspects of pathogenesis of cutaneous leishmaniasis and alternative therapeutics for the disease

14:50-15:20 Elvira Saraiva, Federal University of Rio de Janeiro, Brazil
Close encounters of the NET kind: the abduction of Leishmania

15:20 Closing Remarks

